Tag results:
CD8
Prostate Cell News
Single-Cell Analysis Reveals EP4 as a Target for Restoring T Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy
[Clinical Cancer Research] Investigators identified EP4 as a specific target for prostate cancer immunotherapy and demonstrated that YY001 inhibited the growth of prostate tumors by regulating the immune microenvironment and strongly synergized with anti-programmed cell death protein-1 antibodies.
Extracellular Matrix News
Systemic Delivery of a Targeted Synthetic Immunostimulant Transforms the Immune Landscape for Effective Tumor Regression
[Cell Chemical Biology] To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.
Extracellular Matrix News
Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
[Cancer Research] Researchers revealed that delivery of miR-122 was associated with downregulation of key genes in involved in metastatic and cancer inflammation pathways, including several pro-inflammatory factors, matrix metalloproteinases, and other extracellular matrix degradation enzymes.
Human Immunology News
FGFR3 Destabilizes PD-L1 Via NEDD4 to Control T Cell-Mediated Bladder Cancer Immune Surveillance
[Cancer Research] The authors demonstrated that inhibition of fibroblast growth factor receptor 3 (FGFR3) in FGFR3-activated bladder cancer elevated PD-L1 protein levels by affecting its ubiquitination, thereby inhibiting the anti-tumor activity of CD8+ T cells.
Mesenchymal Cell News
Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection
[Advanced Science] Among various cell sources, FGL1/PD-L1 small extracellular vesicles (sEVs) derived from MSCs not only enriched FGL1/PD-L1 expression but also maintained the immunomodulatory properties of unmodified MSC sEVs.
ESC & iPSC News
Use of Induced Pluripotent Stem Cells to Build Isogenic Systems and Investigate Type 1 Diabetes
[Frontiers in Endocrinology] The authors differentiated iPSC from one donor into dendritic cells, macrophages, endothelial cells, and β-cells, and engineered T cell avatars from the same donor to provide an in vitro platform to study genetic influences on critical cellular interactions.